Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial

B. E. De Galan, S. Zoungas, J. Chalmers, C. Anderson, C. Dufouil, A. Pillai, M. Cooper, D. E. Grobbee, M. Hackett, P. Hamet, S. R. Heller, L. Lisheng, S. MacMahon, G. Mancia, B. Neal, C. Y. Pan, A. Patel, N. Poulter, F. Travert, M. Woodward

Research output: Contribution to journalArticlepeer-review

Abstract

Aims/hypothesis: The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial. Methods: Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n=8,689), 24-27 ('mild dysfunction', n=2,231) and

Original languageEnglish
Pages (from-to)2328-2336
Number of pages9
JournalDiabetologia
Volume52
Issue number11
DOIs
Publication statusPublished - Nov 2009

Keywords

  • Blood pressure control
  • Cardiovascular disease risk
  • Cognitive function
  • Glucose control
  • Hypoglycaemia
  • MMSE
  • Mortality
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial'. Together they form a unique fingerprint.

Cite this